

Form PTO-1595 (Rev. 06/04)

U.S. DEPARTMENT OF COMMERCE
United States Patent and Trademark OfficeRECORDATION FORM COVER SHEET
PATENTS ONLY

To the Director of the U.S. Patent and Trademark Office. Please record the attached documents or the address(es) below..

1. Name of conveying party(ies)/Execution Date(s): Novartis International Pharmaceutical Ltd. Execution Date(s): 12/19/2012 and 2/1/2013 Additional name(s) of conveying party(ies) attached? attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		2. Name and address of receiving party(ies): NAME: SeBo GmbH ADDRESS: Karpfengasse 8 D-69117 Heidelberg, Germany Additional name(s) & addresses(es) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
3. Name of Conveyance: <input checked="" type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input type="checkbox"/> Change of Name <input type="checkbox"/> Government Interest Assignment <input type="checkbox"/> Executive Order 9424, Confirmatory License <input type="checkbox"/> Other			
4. Application number(s) or patent number(s): A. Patent Application No.(s)		<input type="checkbox"/> This document is being filed together with a new application B. Patent No.(s) 5,514,281 5,846,426 6,103,126	
Additional numbers attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No			
5. Name and address of party to whom correspondence concerning document should be mailed: Name: Address: Rothwell, Figg, Ernst & Manbeck Suite 800 Street Address: 607 14 th St., N.W. City: Washington, State: D.C. Zip: 20005 Telephone No.: 202/783-6040 Facsimile No.: 202/783-6031 Email Address: pto-pat-email@rfem.com Attorney Docket No. : 2923-0000		6. Total number of applications and patents involved: <u>3</u> 7. Total fee (37 CFR 3.41): \$ <u>120.00</u> <input type="checkbox"/> Enclosed <input checked="" type="checkbox"/> Authorized to be charged to deposit account <input type="checkbox"/> None required (government interest not affecting title)	
		8. Deposit account number: 02-2135 Authorized User Name <u>Robert B. Murray</u>	
DO NOT USE THIS SPACE			
9. Signature. <u>/Robert B. Murray/</u> <u>March 7, 2013</u> Signature Date <u>Robert B. Murray</u> Total number of pages including cover sheet, attachments and documents: <u>5</u> Name of Person Signing			

Patent Case PAT034425

ASSIGNMENT

This Assignment Agreement is entered into by and between **NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (NIP)**, 131 Front Street, Hamilton, Bermuda, and **SeBo GmbH**, Karpfengasse 8, D-69117 Heidelberg, Germany.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, **NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.** does hereby sell, assign and transfer to **SeBo GmbH** and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of its right, title and interest for all countries of the world in and to

(1) all inventions and discoveries described in the provisional or non-provisional patent application(s) entitled

SEE ATTACHED LIST OF CASES

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees, or on behalf or in the name(s) of the inventor(s) of said inventions and discoveries, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by NIP if this sale, assignment and transfer had not been made.

NIP hereby authorizes ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

NIP hereby covenants and agrees that it will, at any time, (i) upon the request of ASSIGNEE, at the expense of NIP, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, and (ii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, and at the expense of ASSIGNOR.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment is effective as from the earliest priority date as stated above.

Executed this 19th day of December, 2012.

NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.

BY [Signature] L.S.

Witness
Print Name: Rebecca White

[Signature]
Witness
Print Name: ALICIA LAMBERT

Executed this 01 day of February, 2012. 2013

SeBo GmbH

BY [Signature] L.S.

Witness
Print Name: Helga Frey

[Signature]
Witness
Print Name: Brigitte Riemenschneider

Novartis Ref. No.	Weickman Ref. No.	City	Filing Date	Filing Number	Publication	Grant #	Grant Date	Status
PAT034425-AT-EPA	12536P AT-EP	AT	23 Nov 1993	93118828.8	08 Jun 1994	600347	28 Feb 2001	GRT
PAT034425-BE-EPA	12536P BE-EP	BE	23 Nov 1993	93118828.8	08 Jun 1994	600347	28 Feb 2001	GRT
PAT034425-CH-EPA	12536P CH-EP	CH	23 Nov 1993	93118828.8	08 Jun 1994	600347	28 Feb 2001	GRT
PAT034425-DE-EPA	12536P DE-EP	DE	23 Nov 1993	93118828.8	08 Jun 1994	600347	28 Feb 2001	GRT
PAT034425-DE-NP		DE	24 Nov 1992	P4239442.2		4239442.2	13 Sep 2001	GRT
PAT034425-EP-EPA		EP	23 Nov 1993	93118828.8	08 Jun 1994	600347	28 Feb 2001	GRT
PAT034425-ES-EPA	12536P ES-EP	ES	23 Nov 1993	93118828.8	08 Jun 1994	600347	28 Feb 2001	GRT
PAT034425-FR-EPA	12536P FR-EP	FR	23 Nov 1993	93118828.8	08 Jun 1994	600347	28 Feb 2001	GRT
PAT034425-GB-EPA	12536P GB-EP	GB	23 Nov 1993	93118828.8	08 Jun 1994	600347	28 Feb 2001	GRT
PAT034425-IT-EPA	12536P IT-EP	IT	23 Nov 1993	93118828.8	08 Jun 1994	600347	28 Feb 2001	GRT
PAT034425-JP-NP		JP	22 Nov 1993	291843/1993		3406360	07 Mar 2003	GRT
PAT034425-LU-EPA	12536P LU-EP	LU	23 Nov 1993	93118828.8	08 Jun 1994	600347	28 Feb 2001	GRT
PAT034425-NL-EPA	12536P NL-EP	NL	23 Nov 1993	93118828.8	08 Jun 1994	600347	28 Feb 2001	GRT
PAT034425-SE-EPA	12536P SE-EP	SE	23 Nov 1993	93118828.8	08 Jun 1994	600347	28 Feb 2001	GRT
PAT034425-US-DIV		US	06 Apr 1995	08/417844		5514281	07 May 1996	GRT
PAT034425-US-DIV02		US	26 May 1995	08/452397				ABD
PAT034425-US-DIV03		US	07 Oct 1996	08/720925		5846426	08 Dec 1998	GRT
PAT034425-US-DIV04		US	01 Sep 1998	09/145129		6103126	15 Aug 2000	GRT
PAT034425-US-NP		US	17 Nov 1993	08/153567				ABD

PATENT

REEL: 029929 FRAME: 0817

RECORDED: 03/07/2013